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Summary Sera from 40 patients with newly diagnosed bladder cancer (28 superficial tumours (pTa and pTI)
and 12 muscle-invasive tumours) were assessed by enzyme-linked immunosorbent assay (ELISA) to determine
the concentrations of soluble E-cadherin (sE-cadherin), soluble E-selectin (sE-selectin), soluble vascular cell
adhesion molecule-I (sVCAM-1) and soluble intercellular adhesion molecule-I (sICAM-1). Corresponding
frozen sections of primary tumour were analysed for E-cadherin expression using the monoclonal antibody,
HECD-1 and standard immunohistochemistry. Patients with bladder cancer had significantly higher
concentrations of sE-cadherin compared with a control group (P=0.017). No difference was found between
the two groups with regard to sE-selectin (P=0.403), sVCAM-1 (P=0.942) and sICAM-1 (P=0.092). High
levels of sE-cadherin were related to poor histological grade (P=0.009), number of superficial tumours at
presentation (P=0.008) and a positive 3 month check cytoscopy in superficial disease (P=0.036). Abnormal E-
cadherin expression was associated with increasing tumour stage (P=0.009) and grade (P =0.03). There was no
correlation between high levels of soluble E-cadherin in sera and abnormal E-cadherin expression by the
tumour (P= 0.077). Elevated levels of sE-cadherin are found in sera of patients with bladder cancer and
correlate with known prognostic factors.
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Of newly diagnosed superficial bladder tumours, approxi-
mately 30% are multifocal at presentation (Lutzeyer et al.,
1982), 60-70% will recur (Greene et al., 1973) and 10-20%
will undergo stage progression (Lutzeyer et al., 1982). Intense
debate surrounds the exact aetiology of synchronous and
metachronous bladder cancer. Mucosal abnormalities,
namely dysplasia and carcinoma in situ, adjacent and distal
to the primary tumour, are associated with a poor prognosis,
in terms of tumour recurrence and progression in superficial
disease (Althausen et al., 1976; Smith et al., 1986). In
contrast, recent reports, based on molecular biological studies
(Sidransky et al., 1992; Lunec et al., 1992) have added a new
dimension suggesting a common clonal origin for concomi-
tant urothelial tumours, at least in some cases. Lateral
intraepithelial spread of transformed cells from the origin of
a bladder carcinoma or dispersal of tumour cells are possible
mechanisms underlying multifocal disease. In support of
these theories, a single instillation ofintravesical mitomycin C
(Tolley et al., 1988) or epirubicin (Oosterlinck et al., 1993)
immediately following transurethral resection has been
reported to increase time to first recurrence.
Decreased intercellular adhesiveness favours detachment of
tumour cells (Takeichi, 1991) and this may play a role in
multifocality, the development of recurrent superficial
tumours and progression to metastatic disease. At least four
families of cell adhesion molecules are thought to be involved
in cell-cell adhesion (cadherins, selectins, immunoglobulins
and integrins). The most widely studied have been E-
cadherin, a cell-surface glycoprotein restricted to epithelial
tissue (Behrens et al., 1985; Shimoyama et al., 1989), involved
in calcium-dependent homotypic cell -cell adhesion, and
vascular cell adhesion molecules [E-selectin, vascular cell
adhesion molecule 1; (VCAM-1) and intercellular adhesion
molecule 1 (ICAM-1)].
In normal urothelial cells, E-cadherin is homogenously
expressed at all cell-cell borders (Bringuier et al., 1993) but
not by the cell border in contact with the basement
membrane. Loss of expression of E-cadherin on cell
membranes has been reported in patients with high-grade,
muscle-invasive bladder tumours (Bringuier et al., 1993; Otto
et al., 1994; Lipponen and Eskelinen, 1995) and high-grade
prostate cancers (Umbas et al., 1992), in which abnormal
immunohistochemical patterns including cytoplasmic stain-
ing, heterogenous cell membrane expression and negative
staining have been reported. Abnormal expression of E-
cadherin is associated with reduced recurrence-free survival
(Lipponen et al., 1995), along with higher progression rates in
patients with superficial bladder tumours (Otto et al., 1994)
and also reduced survival in patients with muscle-invasive
tumours (Bringuier et al., 1993). It has been suggested that
reduced E-cadherin expression, associated with an increase in
autocrine motility factor receptor (gp78) expression identifies
a group of patients with superficial bladder cancer at high
risk of stage progression and earlier cancer-related death
(Otto et al., 1994). Using bladder carcinoma cell lines and
primary murine urothelium as a model for tumour
recurrence, E-cadherin appears to be an important determi-
nant of the pattern of intraepithelial expansion and the
ability of tumour cells to colonise primary urothelium (Rebel
et al., 1994).
Soluble forms of E-cadherin (sE-cadherin) have been
detected in the urine of healthy individuals and patients
with bladder cancer (Banks et al., 1995). Soluble E-cadherin
fragments have also been found in the sera of patients with
gastric and hepatocellular carcinomas (Katayama et al.,
1994). The molecular weight of the main form of sE-
cadherin detected in urine, 80 kDa, was consistent with that
found in serum in the latter study. Furthermore, an 80 kDa
fragment is unlikely to represent a product filtered from the
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blood by the kidneys and excreted into urine. It is, therefore,
assumed that sE-cadherin detected in serum is a degradation
fragment of intact E-cadherin (120 kDa) found on epithelial
cells.
Adhesion of carcinoma cells to endothelium has been
reported to be mediated by E-selectin in colon carcinoma
(Lauri et al., 1991) and VCAM-1 in malignant melanoma
(Rice and Bevilacqua, 1989). ICAM-1 is associated with
disease progression in a group of patients with malignant
melanoma (Natali et al., 1990). Elevated circulating soluble
variants of E-selectin, VCAM-1 and ICAM-1 have been
found in a variety of cancer patients (Banks et al., 1993).
Elevated soluble ICAM-1 is also associated with reduced
survival in patients with malignant melanoma (Harning et al.,
1991), and in patients with liver metastases in gastric, colonic,
gallbladder and pancreatic cancers (Tsujisaki et al., 1991).
Finally, a recent study has linked soluble VCAM-1 and
soluble E-selectin with the formation of new blood vessels
(angiogenesis), which in turn may promote new tumour
growth (Koch et al., 1995).
The primary objective of this study was to determine the
levels of soluble forms of E-cadherin (sE-cadherin), E-selectin
(sE-selectin), VCAM-1 (sVCAM-1) and ICAM-1 (sICAM-1)
in sera of patients with newly diagnosed transitional cell
carcinoma of the bladder. Our first aim was to assess if any
of these factors correlated with multifocal synchronous or
metachronous tumours in patients with superficial disease or
the presence of metastases at presentation in those patients
with muscle-invasive disease. A further objective was to
compare levels of sE-cadherin in sera with expression of E-
cadherin by the primary bladder tumours assessed by
immunohistochemistry.
Materials and methods
Patients
Samples of venous blood were collected aseptically from 40
patients (36 males and four females) with newly diagnosed
transitional cell carcinoma of the bladder before cystoscopy
and transurethral resection of tumour (TURT). Patient
controls consisted of 13 age- [median age=65 years (95%
confidence interval) (CI)= 58 years to 74 years] and sex- (eight
males, five females) matched patients undergoing elective
surgery for non-malignant conditions including peptic
ulceration, diverticular disease and inguinal herniae. Bladder
tumours were staged using the TNM system (Union
Internationale Contre le Cancer, 1992). Seventeen patients
had Ta tumours, 11 had Tl tumours and 12 patients had
muscle-invasive (T2-T4) tumours. Four patients with super-
ficial tumours and three patients with muscle-invasive tumours
had concomitant carcinoma in situ. Tumours were graded
using the WHO system (Mostofi, 1974). There were five GI, 16
G2 and 19 G3 tumours. The median age ofthe patients was 71
years (CI= 67 years to 74 years). Three of 28 (11%) patients
with superficial disease were given intravesical chemotherapy
following transurethral resection: one patient was given a
single dose of intravesical mitomycin C immediately after
TURT; the other two patients underwent a course of six
instillations of intravesical epirubicin at weekly intervals. In
patients with superficial disease, the number of tumours at
presentation and the outcome of the 3 month check
cystoscopy were noted. In patients with muscle-invasive
disease, the presence of metastases were determined by
computerised tomography (CT) scanning, chest radiography
and the operative findings at cystectomy.
Preparation of venous blood
Venous blood samples were immediately centrifuged at 400 g
for 10 min, allowing separation of serum, which was stored
at -20°C. Before analysis, samples were slowly thawed and
gently mixed.
ELISA
Levels of circulating sE-cadherin (Takara Schuzo Co.,
Kyoto, Japan), sE-selectin, sVCAM-1 and sICAM-1 (R&D
Systems, Abingdon, Oxon, UK) were measured by
commerically available ELISA kits. The immunoassay is
based on simultaneous reaction of the soluble adhesion
molecule in the sample to two anti-human adhesion
molecule antibodies, one antibody coated to the walls of
the microtitre wells, the other conjugated to the enzyme
horseradish peroxidase. The reaction between peroxidase
and substrate results in colour development, intensities of
which are proportional to soluble adhesion molecule levels.
Monoclonal antibodies, HECD-1 and SHE13-6 were used in
the sE-cadherin immunoassay. Their affinities for both the
intact 120 kDa form of E-cadherin on epithelial surfaces and
the soluble 80 kDa fragment of E-cadherin in serum have
been confirmed by Western blot analysis (Katayama et al.,
1994).
Following addition of stop solution, the optical density of
each well was determined immediately by ELISA plate reader
(MR 5000, Dynatech, West Sussex) using dual wavelength
correction (A=450 nm, A=630 nm for correction). Corrected
concentrations of unknown sera were calculated automati-
cally from standard curves.
E-cadherin immunohistochemistry
Samples of bladder tumours were collected at the time of
TURT, and immediately stored at - 80°C. Frozen sections of
tumour corresponding to serum analysis were available for 31
patients (22 superficial and nine muscle-invasive tumours).
Positive controls consisted of biopsies of normal urothelium
from three patients with no evidence of urothelial tumour
and one normal colonic biopsy. For each run, negative
controls were prepared by staining duplicate sections of
tumour using the methods described below, but omitting the
primary antibody.
Frozen sections were cut at 5 ,um, air dried and fixed in
acetone for 10 min. Sections were rinsed in 5 mM Tris
buffered saline (TBS) pH7.6 for 5 min and covered with
normal rabbit serum (NRS) for 10 min. Excess serum was
removed and primary anti-E-cadherin monoclonal antibody,
HECD-l (R&D Systems) was applied at a dilution of 1:400
for 30 min at room temperature. After further washing in
TBS, sections were covered with biotinylated rabbit anti-
mouse immunoglobulin diluted 1:500 in NRS for 30 min.
Following incubation in secondary antiserum, sections were
again rinsed in TBS and covered with tertiary antiserum
consisting of a streptavidin-biotin-peroxidase complex
(1 MI of streptavidin, 1 4ul of biotinylated horseradish
peroxidase and 100 jul of TBS) for 30 min. The reaction
was developed in diaminobenzidine (BDH, Poole, Dorset,
UK) and sections were then counterstained with haematox-
ylin (BDH).
A tumour was defined as having normal E-cadherin
expression if tumour cells displayed positive staining along
cell-cell borders. All other staining patterns were classified as
abnormal.
Statistical analysis
Statistical analysis was performed using Minitab for
Windows (Release 9) software. Data were presented as
medians with 95% confidence intervals (Wilcoxon confi-
dence interval of the median). Distributions were compared
using the Mann-Whitney U-test. In certain cases, the
Mann -Whitney confidence interval for the difference
between two medians was quoted to illustrate the practical
significance. Proportions were compared using Fisher's exact
test. In the above analyses, a P-value of <0.05 was
considered statistically significant.Results
Bladder cancer vs control group patients
The median concentration of sE-cadherin in serum of
patients with bladder cancer was 3955 ng ml-' compared
with a median concentration of sE-cadherin in control
patients of 1013 ng ml-' (P =0.017; CI = 161 -3976 ng ml'-
(Figure 1). No significant difference was found between
patients with bladder cancer and controls with regard to sE-
selectin (P=0.403), sVCAM-1 (P=0.942) or sICAM-1
(P =0.092).
Levels of soluble cell adhesion molecules for patients with
tumours ofdifferent grade and stage are shown in Table I. GI
tumours had similar levels ofsE-cadherin in sera to thecontrols
(P =0.554; CI = -831 to 2092 ng ml '). Highergrade tumours
(G2 and G3) had significantly elevated concentrations of sE-
cadherin in sera compared with the control group (P = 0.011;
CI = 179-5438 ng ml-' (Figure 2) and combined controls/GI
group (P =0.009; CI =207-4690 ng ml-). Significantly ele-
vated levels ofsE-cadherin compared with controls were found
in patients with muscle-invasive (P =0.004; CI =699 -
7173 ng ml-') bladder cancer but not for superficial disease
(P=0.085; CI= -39 to 3663 ng ml-'). Soluble E-cadherin
levels did not differ significantly with tumour stage [Ta vs Ti
tumours, P=0.572 (CI= -3362 to 2235 ng ml-'); Ta vs TI
and muscle-invasive tumours, P =0.753 (CI= -2453 to 1325
ng ml-'); Ta/Ti tumours vs muscle invasive tumours,
P=0.175 (CI= -3141 to 693 ng ml-')].
Solitary vs multifocal superficial tumours
At presentation, 13 of 28 (46%) patients had solitary
superficial tumours and 15 (54%) patients had multifocal
tumours. The concentration of sE-cadherin was significantly
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higher in patients with multifocal tumours (P=0.008;
CI= 681 to 7322 ng ml-1) (Figure 3). Multifocality was not
associated with sE-selectin (P=0.214), sVCAM-1 (P=0.369)
or sICAM-1 (P=0.890).
Tumour bulk
Of 13 patients with solitary superficial tumours, four patients
had tumours greater than 5 cm in diameter. There was no
significant difference in sE-cadherin concentrations in patients
with tumours greater or less than 5 cm in diameter
(P=0.9385; CI=2099-1369 ng ml-'). Similarly, the number
ofmultiple superficial tumours was not related to sE-cadherin
concentration (>three tumours vs two or three tumours,
P=0.871; CI= -6454 to 6607 ng ml-').
Outcome of 3 month check cystoscopy
Three patients with superficial bladder cancer were not
assessed cystoscopically at 3 months following diagnosis
owing to poor general health. One patient with T1G3 disease
had a cystectomy. Seven of 24 patients (29%) with superficial
bladder cancer had a positive 3 month check cystoscopy.
Elevated levels of sE-cadherin at presentation were positively
correlated with a positive 3 month cystoscopy (P=0.036;
CI=65-7374 ng ml-'). The median concentration of sE-
cadherin in patients with a recurrence at 3 months was
7805 ng ml-' (CI=3973-9198 ng ml-l), compared with a
median concentration of 1828 ng ml-' (CI= 1082-
4564 ng ml-') for those patients disease free at 3 months.
Multifocality per se correlated with tumour recurrence at 3
months (Fisher's exact test, P=0.027). One of the 12 solitary
superficial tumours (8%) with 3 month follow-up had a
tumour recurrence at 3 months. In contrast, six of twelve
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Figure 1 Dot plot demonstrating concentrations of soluble E-
cadherin in sera of controls and bladder cancer patients.
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Figure 2 Dot plot demonstrating the relationship between the
concentration of soluble E-cadherin in sera and bladder tumour
grade.
Table I Concentrations of soluble cell adhesion molecules in sera (ng ml-1) related to histological grade and tumour stage
Median (CI) serum concentration ofsoluble adhesion molecule (ng ml-)
E-cadherin E-selectin VCAM-1 ICAM-1
Controls (n= 13) 1013 (655- 1753) 55.8 (40.2-71.0) 783 (540-1102) 458 (340-572)
Tumour (n=40) 3955 (2045-5102) 48.0 (41.0-55.3) 774 (693-868) 348 (311-396)
GI (n=5) 1686 (132-3241) 44.8 (15.6-79.7) 818 (502-1058) 335 (83-587)
G2 (n = 16) 4777 (2236-6644) 51.2 (38.7-65.0) 785 (644-962) 348 (288-419)
G3 (n= 19) 3707 (1397-5497) 7.4 (38.3-55.8) 759 (636-905) 358 (296-427)
Ta (n= 17) 2992 (1596-5100) 6.1 (33.1-59.9) 771 (632-910) 335 (271-411)
TI (n=11) 4294 (428-5622) 57.5 (42.7-69.7) 920 (723-1105) 400 (312-513)
MI (n= 12) 4916 (2056-6711) 44.6 (33.7-54.8) 698 (560-862) 328 (262-394)
MI =Muscle-invasive. CI=95% confidence interval.
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Table II E-cadherin staining related to histological grade and
tumour stage
Normal staining Abnormal staining
(n=20) (n=14)
Normal urothelium (n=3) 3 0
GI (n=3) 3 0
G2 (n=13) 7 6
G3 (n=15) 7 8
Ta(n=13) 11 2
TI (n=9) 4 5
MI (n=9) 2 7
MI= Muscle-invasive. Normal urothelium/Gl vs G2/G3, P=0.03
(Fisher's Exact Test). Ta vs T1/MI, P= 0.009 (Fisher's Exact Test).
olitary (n= 13) Multifocal (n= 15)
Superficial bladder tumours
Figure 3 Dot plot demonstrating concentrations of soluble E-
cadherin in sera of patients with solitary or multifocal superficial
tumours at presentation.
(50%) patients with multifocal superficial tumours had a
recurrence at 3 months. Tumour recurrence at 3 months was
not associated with sE-selectin (P=0.703), sVCAM-1
(P=0.105) or sICAM-1 (P=0.228).
sE-cadherin and metastatic disease
Eight of twelve patients with muscle-invasive tumours had no
evidence of metastatic disease on CT scanning. Three of the
eight patients were later treated by cystectomy, three
underwent radiotherapy and two were treated by transure-
thral resection alone. One of the three patients treated by
cystectomy was found to have metastatic lymph node
involvment at the time of surgery. A systematic assessment
for metastases was not performed in the remaining four
patients as they were considered too frail for radical
treatment. Preliminary data suggest that patients with
muscle-invasive disease but no evidence of metastases at
presentation have a wide range of concentrations of sE-
cadherin in sera (median=2588 ng ml-'; CI= 1010-
6737 ng ml-').
E-cadherin immunohistochemistry
In normal urothelium and normal colon, E-cadherin was
expressed at cell-cell borders as expected. Of 31 tumours, 17
(55%) showed a similar staining pattern to normal
urothelium. Abnormal E-cadherin expression was detected
in the remaining 14 tumours (heterogenous membrane
staining in 13 and perinuclear staining in one). Correlation
of staining patterns with tumour stage and grade is shown in
Table II. Abnormal E-cadherin staining pattern correlated
with tumour stage (Ta vs TI and muscle invasion; Fisher's
exact test, P=0.009). The three well-differentiated tumours
were found to have normal E-cadherin expression. In
contrast, 14 of 28 (50%) moderately and poorly differ-
entiated tumours displayed abnormal E-cadherin expression
(urothelial controls/GI vs G2/G3, Fisher's exact test,
P=0.03). Abnormal E-cadherin staining did not correlate
with elevated sE-cadherin in serum (P=0.077).
Abnormal E-cadherin expression was not related to the
number of superficial tumours at presentation (Fisher's exact
test, P =0.350), or the presence of tumour recurrence at the 3
month check cystoscopy (Fisher's exact test, P = 1.000). Of
seven patients with non-metastatic muscle invasive disease,
three had heterogeneous E-cadherin expression. Conversely,
one patient with evidence of perivesical lymphatic metastatic
disease, detected at cystectomy, had normal E-cadherin
staining.
Discussion
This is the first report of elevated sE-cadherin in the sera of
patients with bladder cancer. In this study, all patients were
newly diagnosed in comparison with a previous study
reporting significantly elevated levels of sVCAM-l and
sICAM-l in six patients with bladder cancer (Banks et al.,
1993), who were at various stages of therapy, making
interpretation difficult. Also, it is known that interleukin 2
leads to induction of sICAM-1 in sera of patients with
malignant melanoma (Becker et al., 1992).
Multiple tumours at presentation and the presence of
tumours at 3 months are associated with shorter recurrence-
free intervals and higher recurrence rates respectively in
multivariate analysis (Parmar et al., 1989; Reading et al.,
1995). Parmar has suggested that patients with the longest
tumour-free interval and the lowest recurrence rates were those
who have solitary superficial tumours at presentation that do
not recur at 3 months. Eleven of24(46%) patients in this study
were in this category and had lower concentrations of sE-
cadherin at presentation (P=0.011; CI =690-7460 ng ml-')
compared with the other 13 patients with superficial bladder
cancer. Patients with the lowest risk of recurrence, as defined
by Parmar, had a median sE-cadherin concentration of
1462 ng ml-I at presentation compared with a median sE-
cadherin concentration of 5648 ng ml-' for the remainder
(Figure 4). There was no significant difference between these
two groups with regard to the concentrations of sE-selectin
(P=0.118), sVCAM-1 (P=0.543) or sICAM-1 (P=0.954).
Several lines of evidence indicate that E-cadherin plays a
role in regulating the cohesiveness of epithelial tissues
(Takeichi, 1991). Regulation of the expression of E-cadherin
on tumour cells is unclear. In prostate cancer, acorrelation has
been shown between chromosome 16q deletions and abnormal
expression of E-cadherin (Umbas et al., 1992). E-cadherin
may, therefore, behave as a classical tumour-suppressor gene.
Deletion of one allele may be accompanied by inactivating
point mutation in the corresponding allele. Post-translational
modification ofthe protein product may also affect function. It
is known that three molecules (a, ,B and y catenins) form
bridges between the cytoplasmic tail of E-cadherin and the
cytoskeleton that may be necessary for E-cadherin to function
normally (Nagafuchi and Takeichi, 1988).
Our findings are consistent with a previous study showing
that abnormal E-cadherin expression correlates with high
stage, although, in our series, abnormal E-cadherin expres-
sion was commonly detected not only in muscle-invasive
disease (Bringuier et al., 1993; Otto et al., 1994) but also in
TI disease.
In this study, abnormal E-cadherin staining was not
accompanied by high serum levels of sE-cadherin. Con-
versely, in some patients, homogeneous expression of E-
cadherin was found despite elevated levels of sE-cadherin in
serum. It is possible, therefore, that levels of sE-cadherin in
serum reflect the rate of turnover of E-cadherin whereas E-
cadherin expression also reflects genetic abnormalities.Cell adhesion molecules in bladder cancer
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Figure 4 Dot plot comparing concentrations of soluble E-
cadherin in sera of patients with superficial bladder cancer with
low, intermediate and high risk for tumour recurrence. Group 1
patients (low risk), solitary tumour at presentation, no recurrence
at 3 months; group 2 patients (intermediate risk), either (a)
solitary tumour at presentation, tumour recurrence at 3 months
or (b) multiple tumours at presentation, no recurrence at 3
months. Group 3 patients (high risk), multiple tumours at
presentation, tumour recurrence at 3 months.
Our results show that elevated sE-cadherin is found in
patients who are at risk of developing early tumour
recurrence following TURT, and may prove to be a useful
serum marker. Levels ofsE-selectin, sVCAM-1 and sICAM-1
in sera appear to have less significance in bladder cancer. It is
possible that sE-cadherin reflects some aspect of the
pathogenesis of multifocal tumours and development of
tumour recurrence. Interestingly, it has been demonstrated
that sE-cadherin itself interferes with cell-cell adhesion
(Wheelock et al., 1987) in cultured epithelial cells. This
implies that sE-cadherin may be directly involved in the
adhesive process, rather than merely being a degradation
product of intact E-cadherin. It is also conceivable that sE-
cadherin detected in serum is derived from cellular E-
cadherin given that the transmembrane form of E-cadherin
(a 120 kDa glycoprotein) can be degraded to a 80 kDa
soluble product in vitro (Takeichi, 1991; Wheelock et al.,
1987) and that sE-cadherin has also been detected in urine
(Banks et al., 1995). Further studies are needed to determine
if elevated sE-cadherin in sera is associated with high
recurrence rates in superficial bladder cancer and to
determine its relationship with progression to muscle
invasion, the development of metastatic disease and reduced
survival.
The precise relationship between abnormal expression of
E-cadherin and genetic aberrations such as chromosome 16q
deletion needs to be evaluated in bladder tumours as well as
elucidation of factors regulating the degradation of the intact
trans-membrane form of E-cadherin to the soluble form.
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